CN119176855B - 一种提高免疫力的鳄鱼血肽复合物及其制备方法 - Google Patents
一种提高免疫力的鳄鱼血肽复合物及其制备方法 Download PDFInfo
- Publication number
- CN119176855B CN119176855B CN202411405839.3A CN202411405839A CN119176855B CN 119176855 B CN119176855 B CN 119176855B CN 202411405839 A CN202411405839 A CN 202411405839A CN 119176855 B CN119176855 B CN 119176855B
- Authority
- CN
- China
- Prior art keywords
- yzb
- polypeptide
- crocodile
- amino acid
- crocodile blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 82
- 241000270722 Crocodylidae Species 0.000 title claims abstract description 29
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 title claims abstract description 29
- 210000004369 blood Anatomy 0.000 title claims abstract description 22
- 239000008280 blood Substances 0.000 title claims abstract description 22
- 230000036039 immunity Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 57
- 229920001184 polypeptide Polymers 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 7
- 210000002865 immune cell Anatomy 0.000 abstract description 5
- 241000972006 Crocodylus siamensis Species 0.000 abstract description 4
- 230000005965 immune activity Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- -1 superoxide anions Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920001231 Polysaccharide peptide Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 108010022457 polysaccharide peptide Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241000222355 Trametes versicolor Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001515 polyalkylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 244000298800 Actinidia arguta Species 0.000 description 2
- 235000016416 Actinidia arguta Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000252132 Pleurotus eryngii Species 0.000 description 1
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种提高免疫力的鳄鱼血肽复合物及其制备方法。本发明从养殖的暹罗鳄血液中通过酶解、筛选鉴定得了2个具有较好促进免疫细胞增殖及提高免疫活性的多肽,将其制备成为复合物后能够很好的提高小鼠的免疫活力,具有较好的应用价值。
Description
技术领域
本申请涉及生物领域,涉及一种提高免疫力的鳄鱼血肽复合物及其制备方法。
背景技术
免疫系统是人体抵抗外来病原体,提高生存能力的至关重要的一部分,但它容易受到不良生活方式、病菌、压力等诸多因素的干扰。一旦人体免疫系统出现问题,通常通过他克莫司(FK506)、环孢菌素、雷帕霉素、咪唑立宾等免疫抑制剂调节免疫能力。但大多数免疫抑制剂疗效缓慢且有一定的毒副作用。而近年来研究人员发现天然的生物活性肽可能成为治疗免疫疾病的一大突破点。
海洋蕴藏巨大的生物资源,拥有丰富多样的物种以及独特的化学物质。鱼类、贝类、软体动物、甲壳类动物等海洋生物及其副产物是优质蛋白质的丰富来源。从海洋生物来源的多肽具有抗氧化、调节血压、抗菌、抗癌、增强免疫等功能。例如,从发酵鱼露中获得了具有较强抗氧化活性的两个肽段;大眼金枪鱼鱼头蛋白小于1kDa组分对羟自由基、超氧阴离子等有较好的清除能力和提高免疫能力。
此外,植物蛋白大米蛋白主要含有谷蛋白、球蛋白和醇溶蛋白,其主要优点是氨基酸组成合理与低致敏性。目前大米蛋白肽主要集中于抗氧化及降血压活性的研究一,但对大米免疫活性肽的研究也越来越受到重视。最早在1994年Takahashi等就从大米胰酶水解物中分离出一个八肽,并证明其具有增强巨噬细胞吞噬能力、促进肠道收缩和抗吗啡等免疫调节作用,之后也有一些阿片类活性的大米肽相继被分离出来。最近,王璐等圳通过胰酶水解分离纯化出的不同纯度的大米肽能促进巨噬细胞RAW164.7的增殖,分子量≤1000Da的酶解肽具有最佳的促增殖效果。研究发现富硒大米蛋白酶解物可以保护Pb引起的RAW264.7巨噬细胞毒性,表明大米活性肽对免疫细胞具有免疫保护作用。
其他植物来源的免疫活性肽食源性植物种类众多,水果及蔬菜等同样成为免疫活性肽的主要来源。对软枣猕猴桃多肽进行免疫试验,发现软枣猕猴桃多肽能够延长小鼠负重游泳时间、增加小鼠肝糖原储备量、增强动物运动耐力、缓解动物体力疲劳的作用,对小鼠机体具有直接的免疫增强作用。从苋菜中分离得到的蛋白活性肽SSEDIKE可抑制人结肠癌细胞Caco-2的趋化因子CC120的基因表达,具有抑制炎症的免疫特性。从蜜桔中分离出环肽citrusinXl,并利用RAW264.7炎症模型证明其可通过抑制NF-xB通路而降低iNOS和N的产生,具有抗炎作用。此外,来自羽扇豆的抗炎免疫活性肽GPETAFLR可作用于人单核细胞株THP-1分化的巨细胞并明显降低促炎介质TNF、1L-18和CCL2,提高抗炎介质IL-10的基因表达。这些免疫活性肽的研究不仅表明食源性植物的生物活性,同样为食源性植物在生产中的充分利用及临床疾病的改善提供了更多契机。
菌类免疫活性肽菌类蛋白是一种特殊的蛋白质,其氨基酸分子呈线性排列,根据菌种的不同,可产生不同的蛋白质。菌类蛋白的粗提取物及从中分离的多肽、多糖肽(PSP)与环肽在体内外均具有免疫调节活性。分别从冬虫夏草与杏鲍菇中分离提取出抗菌肽,这些肽对多种致病菌增殖有明显抑制作用。研究发现云芝PSP可以调节人外周血单核细胞的Toll样受体4、5信号通路,证明云芝糖肽具有体外免疫活性。在大鼠体内研究中发现云芝PSP可以增高LPS诱导的大鼠血清中的TNF-a和IL-6的含量,证明PSP具有体内免疫调节功能。
鳄鱼多肽营养丰富,是一种高蛋白、低糖、低脂的产品,富含钾、钙、镁和锌、铁等多种金属元素。而且氨基酸种类齐全,富含8种人体必需氨基酸,尤其人体需要量最大的赖氨酸和亮氨酸含量显著较多,并且鳄鱼活性多肽中支链氨基酸与芳香族氨基酸的比值显著高于各种鱼类。研究表明,鳄鱼活性肽能够有效清除对人体有害的自由基,提高机体抗氧化能力,减少氧化产物的产生,保护机体免受各种氧化性损伤,从而预防了各种与自由基损伤相关的疾病,如高血压、糖尿病、阿尔兹海默病、心血管病等。如鳄鱼皮胶原活性肽就能够有效抑制血管紧张素转化酶,从而达到降血压的效果;鳄鱼肉活性肽可以修复受损细胞,提高胰岛细胞功能,促进胰岛素的分泌和胰岛功能的实现,同时提高抗氧化酶的作用,减少氧化作用,减少糖尿病并发症发生。鳄鱼肽富含抗氧化剂,这些成分能够中和自由基,减少细胞损伤,从而加强免疫系统的功能。抗氧化剂不仅可以提升免疫细胞的活力,还可以抑制炎症反应,帮助维持整体健康。
但是目前,一方面,高活性的鳄鱼多肽分离的种类还不够多,另外一方面,鳄鱼数量有限,制备方法复杂,成本高昂,多肽来源受限,不适于直接通过从鳄鱼肉或者鳄鱼血中分离制备获得活性多肽。
发明内容
本发明提供一种提高免疫力的鳄鱼血肽复合物。
进一步的,本发明的鳄鱼血肽复合物是由YZB-II-B-1和YZB-II-B-2多肽组成。
进一步的,YZB-II-B-1多肽的氨基酸序列如SEQ ID NO:1所示,YZB-II-B-2多肽的氨基酸序列如SEQ ID NO:2所示。
进一步的,本发明的多肽还可以被取代。具体的,氨基酸取代可以是保守氨基酸取代。保守氨基酸取代可以是,例如作为酸性氨基酸的天门冬氨酸-谷氨酸;作为碱性氨基酸的赖氨酸/精氨酸/组氨酸;作为疏水氨基酸的亮氨酸/异亮氨酸、甲硫氨酸/缬氨酸、丙氨酸/缬氨酸;作为亲水氨基酸的丝氨酸/甘氨酸/丙氨酸/苏氨酸。保守氨基酸取代也包括基于侧链的分组。例如,具有脂肪族侧链的一组氨基酸是甘氨酸、丙氨酸、缬氨酸、亮氨酸和异亮氨酸;具有脂肪族-羟基侧链的一组氨基酸是丝氨酸和苏氨酸;具有含有酰胺的侧链的一组氨基酸是天冬酰胺和谷氨酰胺;具有芳香族侧链的一组氨基酸是苯丙氨酸、酪氨酸和色氨酸;具有碱性侧链的一组氨基酸是赖氨酸、精氨酸和组氨酸;具有含硫侧链的一组氨基酸是半胱氨酸和甲硫氨酸。进行氨基酸取代后,使用本文所述的测定可以评估含有氨基酸取代的多肽的活性。
进一步的,本发明的多肽还可以偶联聚合物以提高生物活性或者半衰期。
具体的,偶联到多肽的聚合物分子可以是任何合适的聚合物分子,具有依据本发明所限定的分子量,包括天然的和合成的均聚物,诸如多元醇(即聚-OH)、聚胺(即聚-NH2)和聚羧酸(即聚-COOH),以及进一步地,杂聚物,即包括一个或多个不同的偶联基团如羟基基团或胺基团的聚合物。合适的聚合物分子的例子包括选自下列的聚合物分子:聚环氧烷烃(PAO),诸如聚亚烷基二醇(PAG),包括聚乙二醇(PEG)、甲氧基聚乙二醇(mPEG)和聚丙二醇、PEG-缩水甘油醚(Epox-PEG)、PEG-氧羰基咪唑(CDI-PEG)支链聚乙二醇(PEGs)、聚乙烯醇(PVA)、聚羧酸酯、聚乙烯吡咯烷酮、聚-D,L-氨基酸、聚乙烯顺丁烯二酸酸酐共聚物、聚苯乙烯苹果酸酸酐共聚物、葡聚糖包括羧甲基-葡聚糖、肝素、同源白蛋白、纤维素,包括甲基纤维素、羧甲基纤维素、乙基纤维素、羟乙基纤维素、羧乙基纤维素和羟丙基纤维素,壳聚糖的水解物,淀粉诸如羟乙基-淀粉和羟丙基-淀粉、糖原、琼脂糖和其衍生物,瓜尔豆胶、短醒霉多糖、菊糖、黄原胶、卡拉胶、果胶、海藻酸水解产物和生物多聚物。优选的聚合物分子是无毒性的聚合物分子,诸如(m)聚乙二醇(mPEG),进一步地,它们需要相对简单的化学过程便能够共价偶联到酶表面上的附着基团。
进一步的,本发明还提供了YZB-II-B-1和YZB-II-B-2多肽组成的鳄鱼血肽复合物在制备用于提高免疫力的药物中用途。
具体的,所述的药物中含有合适的载体或者赋形剂或者合适的药用辅料。
进一步的,药物可以含有:稀释剂,诸如乳糖、蔗糖、磷酸氢钙或羧甲基纤维素;润滑剂,诸如硬脂酸镁、硬脂酸钙和滑石;和粘合剂,诸如淀粉、天然胶,例如阿拉伯胶、明胶、葡萄糖、糖蜜、聚乙烯吡咯烷、纤维素和其衍生物,聚维酮、交聚维酮和其他这样的粘合剂,如本领域技术人员所知道的。液体的药学上可施用的组合物可以通过例如将上面定义的活性化合物和可任选的药物佐剂溶解、分散或混合在载体中,从而形成溶液或悬浮液来制备,所述的载体例如水、盐水、含水右旋糖、丙三醇、乙二醇、乙醇和类似物。如果需要的话,待施用的药物组合物也可以含有很小量的无毒辅助物质诸如润湿剂、乳化剂或增溶剂、pH缓冲剂和类似物,例如醋酸盐、柠檬酸钠、环状糊精衍生物、脱水山梨醇单月桂酸酯、三乙醇胺醋酸钠、三乙醇胺油酸盐和其他这样的试剂。制备这样的剂型的方法是已知的,或对于本领域技术人员是显而易见的。待施用的组合物或制剂含有一定数量的活性化合物,该数量足以改善接受治疗的对象的症状。此外,抗细菌或抗真菌试剂—包括但不限于硫柳汞可以存在于制剂中。本文中提供的另一制剂是于EDTA、NaCl和CaCl2中的稳定化溶液,其中含有有效活性数量的多肽,并加入了乳糖。本文也提供了含有处于EDTA、NaCl和CaCl2中的稳定化溶液或冻干形式的多肽制剂。本文中提供的另一制剂,或者是冻干的或者是作为稳定溶液,含有有效数量的多肽,它们处于EDTA、NaCl和CaCl2中。
进一步的,所述的药物可以是口服制剂或者注射制剂。
更进一步的,用于肠胃外施用的制剂可以包括普通的赋形剂、无菌水、盐水、诸如聚乙二醇的聚烷撑二醇、植物源油、氢化萘和其组合。在一些实例中,生物相容的、生物可降解的交酯聚合物、交酯/乙交酯共聚物、聚氧乙烯(polyoxethylene)-聚氧丙烯共聚物或其组合可以被用作体内多肽控释的赋形剂。可以使用的其他合适的肠胃外给药系统包括但不限于乙烯醋酸乙烯酯共聚物颗粒、渗透泵、可移植输注系统、脂质体和其组合。用于吸入施用的制剂可以包括诸如乳糖的赋形剂。吸入制剂可以是含有诸如聚氧乙烯-9-月桂醚、甘胆酸盐、脱氧胆酸盐或其组合的水溶液,或者它们可以是以滴鼻剂形式施用的油溶液。如果需要,含有本文提供的多肽的组合物可以配制成凝胶以在鼻内应用。用于肠胃外施用的制剂可以包括口腔施用的甘胆酸盐。为了口服施用,可以使用合适的方法和药学可接受赋形剂制备片剂或胶囊剂,所述赋形剂如粘合剂(例如预胶化玉米淀粉、聚乙烯吡咯烷酮或羟丙基甲基纤维素);填料(例如乳糖、微晶纤维素或磷酸氢钙);润滑剂(如硬脂酸镁、滑石或二氧化硅);崩解剂(如马铃薯淀粉或淀粉羟乙酸钠(sodiumstarch glycolate));或润湿剂(例如月桂硫酸钠(sodium lauryl sulfate))。使用合适的方法可以包衣片剂。可以配制口服施用的制品以提供多肽的控释。
进一步的,本发明的还提供了一种用于提高免疫力的保健品,所述保健品中含有提高免疫力的鳄鱼血肽复合物。本发明的鳄鱼血肽复合物是由YZB-II-B-1和YZB-II-B-2多肽组成。
进一步的,本发明还提供了鳄鱼血肽复合物在制备用于提高免疫力的保健品中的用途,具体的所述的鳄鱼血肽复合物是由YZB-II-B-1和YZB-II-B-2多肽组成。
有益效果
本发明提供了一种提高免疫力的鳄鱼血肽复合物及其制备方法。本发明从养殖的暹罗鳄血液中通过酶解、筛选鉴定得了2个具有较好促进免疫细胞增殖及提高免疫活性的多肽,将其制备成为复合物后能够很好的提高小鼠的免疫活力,具有较好的应用价值。
附图说明
图1 各组分对RAW264.7细胞增殖的影响
具体实施方式
本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。以下实施案例中的方法、设备、材料,如果未进行特别说明,均为本领域常规方法、设备和材料,均可由市场购得。
实施例1 鳄鱼血肽的制备
取养殖的暹罗鳄血液,加入4倍量的蒸馏水,调节至适宜的pH,加入优化后的酶解条件:反应温度为50℃,pH之为7.0,酶与底物浓度比为6%,底物浓度为7.5%,反应为85min。将反应后的产物放入95℃水浴15min,对酶灭活,灭活液在4℃、4500r/min离心30min,取上清液真空浓缩后冷冻干燥,得酶解物。采用D101大孔吸附树脂对暹罗鳄血液酶解物进行脱盐,用截留分子量为3kDa和1kDa的超滤膜超滤分级,得三个组分:YZB-I(MW>3kDa)、YZB-II(3kDa>MW>1kDa)和YZB-III(MW<1kDa)。
RAW264.7细胞系(货号:HTX1760,豪地华拓生物)培养于含有10%灭活胎牛血清的高糖DMEM 培养基中,置于 37℃、饱和湿度5%CO2恒温培养箱中进行培养,每2-3d传代一次。取对数生长期细胞,调整细胞浓度为5×105个/mL,以100μL孔接种于96孔培养板中,于37℃、5%CO2恒温培养箱中培养2h,待细胞贴壁,去掉上清液,每孔加入100μL三个超滤分级组分,使其终浓度为1μg/mL(含10%胎牛血清的高糖DMEM培养基配制),空白对照组加入不含多肽组分的培养液,以1μg/mL LPS作为阳性对照组,每组设置3个复孔。在37℃、5%CO2恒温培养箱中继续培养24h后,加入10μL 5mg/mL的MTT工作液,继续培养4h,弃去培养基,小心用PBS冲3遍后,每孔加入150μL DMSO溶解液,避光振荡20min,使甲瓒彻底溶解利用酶标仪测570nm处的OD值,计算RAW264.7细胞增殖率,增殖率(%)=(样品OD570nm/空白对照组OD570nm)×100。
从图1可以看出,YZB-II(3kDa>MW>1kDa)组分的促进细胞增殖能力最强,相比空白对照组,增殖率达到了(165.4±3.7)%,因此,选择该组分进行进一步的分离和纯化。
取超滤后的 YZB-II溶于双蒸水中,保持浓度为1mg/mL,加入到预先平衡的Sephadex G-25 凝胶柱(2.6× 80cm)上,用蒸馏水以1mL/min的速度洗脱,每5min收集一管, 并于220nm检测吸光度,按峰合并,得5个组分(YZB-II-A~E)。采用前述相同的RAW264.7细胞增殖率(%)检测方法,检测五个组分对RAW264.7细胞增殖的影响,结果显示,YZB-II-B组分显示出最强的增殖效果。
将YZB-II-B组分进行RP-HPLC。RP-HPLC条件为:色谱柱Zorbax SB C-18(4.6×250mm,5μm,Agilent,USA);流速1mL/min;检测波长220nm;流动相:乙腈/水梯度洗脱;柱温25℃。YZB-II-B经RP-HPLC分析为2个峰,分别命名为YZB-II-B-1和YZB-II-B-2。利用Edman降解法经蛋白质序列分析仪测定YZB-II-B-1的序列为SEQ ID NO:1所示,YZB-II-B-2的序列为SEQ ID NO:2所示。
实施例2 鳄鱼血肽对免疫细胞吞噬活性的影响
RAW264.7细胞系(货号:HTX1760,豪地华拓生物)培养于含有10%灭活胎牛血清的高糖DMEM 培养基中,置于 37℃、饱和湿度5%CO2恒温培养箱中进行培养,每2-3d传代一次。取对数生长期细胞,调整细胞浓度为5×105个/mL,设置空白对照组(只有培养基)、阳性对照组(1μg/mL LPS)和YZB-II-B-1和YZB-II-B-2 分别2个质量浓度的实验组(10μg/mL、100μg/mL),每组设置4 个复孔,在 37℃、5%CO2条件下培养 24h后弃掉上清液,加入0.075%中性红溶液100uL,于37℃、5%CO2培养箱中继续培养1h,弃去中性红溶液,小心用PBS 洗2遍后,加入醋酸-乙醇(1:1,V/V)细胞溶解液100μL/孔,室温静置过夜,利用酶标仪,于波长540 nm处测定 OD值,按照下面公式计算 RAW264.7细胞的吞噬指数。吞噬指数(%)=(样品OD540nm/空白对照组OD540nm)×100。结果如表1所示。
表1 各组的吞噬指数结果
#表示与空白对照组相比,差异显著(P<0.05)。
从表1可以看出,本发明的YZB-II-B-1和YZB-II-B-2多肽对RAW264.7细胞刺激后,对细胞吞噬能力有明显的促进作用,并且具有一定的剂量依赖性,与空白对照组相比,差异显著(P<0.05)。
实施例3 鳄血多肽对小鼠免疫力的影响
将BALB/c小鼠,每组10只随机分为6个组:对照组、模型组、阳性对照组(鱼鳞胶原蛋白多肽400mg/kg)组(货号XCSW2022,香草生物)、YZB-II-B-1和YZB-II-B-2(1:1)多肽共计200、400、800mg/kg组。造模同时开始灌胃给药,每天1次,连续15d。对照组给予饮用水0.2mL/10g体重。造模方法除对照组外,其余各组小鼠腹腔注射环磷酰胺,0.6mg/次,每日1次,共3次,对照组腹腔注射等量生理盐水0.2mL/10g体重。连续对小鼠灌胃15d,将其颈椎脱臼处死,无菌条件下获取其脾脏,用镊子将脾在盛有适量无菌Hanks液的小平皿中轻轻撕碎,200目筛网过滤制成单细胞悬液,悬液分为2部分,用于转化实验备用。细胞悬液用Hanks液洗涤2次,每次进行10min(1000r/min)离心,然后将细胞悬浮于1mL的完全培养液中,台盼兰染色计数活细胞数(在95%以上),将细胞浓度调整为3×106个/mL。每份细胞悬液分两孔加入24孔培养板中,每孔1mL,一孔加75μLConA液作为实验,另一孔作为对照,置培养箱中培养72h。培养结束前4h,每孔吸去上清液0.7mL,加入0.7mL不含血清的RPMI1640培养液,同时加入MTT50μL/孔,继续培养4h。培养结束后,每孔加入1mL酸性异丙醇,吹打混匀,使紫色结晶完全溶解。然后分装到96孔培养板,每孔做3个平行孔,用酶标仪以570nm波长测定光密度值。以实验孔与对照孔OD的差值代表淋巴细胞增殖能力。结果如表2所示。
表2 各组对免疫功能损伤小鼠脾淋巴细胞增殖功能的影响
*表示与模型组相比,P<0.05。
从表2的结果表明给药组小鼠T淋巴细胞的增殖功能较模型组小鼠的功能有明显上升,并且具有计量依赖性,在800mg/kg给药条件下,增殖能力最强。
进一步的,将各组小鼠脾细胞悬液(5×106/L)加入96孔细胞培养板内,100μL/孔。将体外传代培养的YAC-1靶细胞(51Cr标记靶细胞)离心,并调整细胞密度按照效靶比为10:1,加于96孔培养板中,置37℃、CO2培养箱中培养4h。1000rpm离心培养板10min,吸取100μl上清液至检测管中,采用液闪计数仪检测每分钟放射性活性(cpm值),计算NK细胞对靶细胞的杀伤率。结果如表3所示。
表3 各组对免疫功能损伤小鼠NK细胞杀伤活性的影响
*表示与模型组相比,P<0.05。
从表3的不同组别的NK细胞杀伤结果显示,阳性对照组以及本发明的多肽组,而且具有正向免疫调节作用,可提高小鼠的免疫功能,且呈一定的剂量依赖性。基于以上结果可以发现,本发明的YZB-II-B-1和YZB-II-B-2多肽制备的组合物药物可以有效的提高机体的免疫力,具有极好的治疗效果和应用前景。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (4)
1.一种提高免疫力的鳄鱼多肽,其特征在于其命名为YZB-II-B-1多肽,其氨基酸序列如SEQ ID NO:1所示。
2.一种提高免疫力的鳄鱼多肽,其特征在于其命名为YZB-II-B-2多肽,其氨基酸序列如SEQ ID NO:2所示。
3.一种提高免疫力的鳄鱼血肽复合物,其特征在于所述的复合物是由YZB-II-B-1和YZB-II-B-2多肽按照1:1配制组成,其中,YZB-II-B-1多肽的氨基酸序列如SEQ ID NO:1所示,YZB-II-B-2多肽的氨基酸序列如SEQ ID NO:2所示。
4.鳄鱼血肽复合物在制备提高免疫力的药物中的用途,其中,所述的复合物是是由YZB-II-B-1和YZB-II-B-2多肽按照1:1配制组成,其中,YZB-II-B-1多肽的氨基酸序列如SEQ ID NO:1所示,YZB-II-B-2多肽的氨基酸序列如SEQ ID NO:2所示。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411405839.3A CN119176855B (zh) | 2024-10-10 | 2024-10-10 | 一种提高免疫力的鳄鱼血肽复合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411405839.3A CN119176855B (zh) | 2024-10-10 | 2024-10-10 | 一种提高免疫力的鳄鱼血肽复合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119176855A CN119176855A (zh) | 2024-12-24 |
| CN119176855B true CN119176855B (zh) | 2025-04-25 |
Family
ID=93897747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411405839.3A Active CN119176855B (zh) | 2024-10-10 | 2024-10-10 | 一种提高免疫力的鳄鱼血肽复合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119176855B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567773A (zh) * | 2016-01-18 | 2016-05-11 | 广州市鼍龙生物技术开发有限公司 | 一种鳄鱼血多肽粉的制备方法及其产品与应用 |
| CN111087447A (zh) * | 2020-01-03 | 2020-05-01 | 福建鼍龙实业有限责任公司 | 一种鳄鱼抗氧化肽复合物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180264050A1 (en) * | 2015-06-04 | 2018-09-20 | Hector Manuel Zepeda López | (en) potentiated t-cell modulator able to modulate immune response, method for extracting, testing and counting a dialysable leucocyte extract from shark spleen to produce same, and therapeutic use thereof |
| CN118184742B (zh) * | 2024-03-21 | 2025-02-18 | 福建农林大学 | 缓解吡虫啉诱导免疫损伤的带鱼免疫肽fafu-c及其制备方法 |
| CN118240016A (zh) * | 2024-03-22 | 2024-06-25 | 海南大学 | 一种双向免疫调节的活性肽及其应用 |
-
2024
- 2024-10-10 CN CN202411405839.3A patent/CN119176855B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105567773A (zh) * | 2016-01-18 | 2016-05-11 | 广州市鼍龙生物技术开发有限公司 | 一种鳄鱼血多肽粉的制备方法及其产品与应用 |
| CN111087447A (zh) * | 2020-01-03 | 2020-05-01 | 福建鼍龙实业有限责任公司 | 一种鳄鱼抗氧化肽复合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119176855A (zh) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060946A (ja) | 免疫機能を調節するため及び腸の炎症を治療するためのベータ-1,3-グルカンの使用 | |
| CN101475632B (zh) | 具有抗肿瘤作用的重组灵芝免疫调节蛋白及其药物制剂 | |
| CN115772550B (zh) | 一种具有抗氧化活性和保肝功效的草菇多肽的制备方法 | |
| NZ509622A (en) | Peptides based on the sequence of human lactoferrin and their use | |
| WO2017180760A1 (en) | Methods to facilitate the solubilization of beta-1,3-glucan and enhance immune function and other related uses | |
| CN115010787B (zh) | 一种苦荞活性肽及其制备方法和新用途 | |
| US20030044424A1 (en) | Novel immune enhancing compositions | |
| CN114891067A (zh) | 一种蒲公英抗炎活性肽及其制备方法与应用 | |
| CN119176855B (zh) | 一种提高免疫力的鳄鱼血肽复合物及其制备方法 | |
| WO1996032123A1 (en) | Pharmaceutical preparations derived from korean mistletoe | |
| CN114989248B (zh) | 一种具有抗炎抗氧化活性的忧遁草多肽及其制备方法和应用 | |
| CN101157726A (zh) | 亚血红素短肽化合物及在抗白内障药物制备中的用途 | |
| EP2087899B1 (en) | Grifola frondosa-derived substance having anti-influenza virus activity and method for producing the same | |
| WO1996032121A1 (en) | Pharmaceutical preparations derived from european mistletoe | |
| CN115887689B (zh) | β-葡聚糖与M2巨噬细胞靶向肽偶联物、制备方法及重塑肿瘤微环境和免疫抗肿瘤的应用 | |
| KR20250075462A (ko) | 버섯 균사체 추출발효물을 유효성분으로 포함하는 염증성 골관절질환 치료 또는 예방용 조성물 | |
| CN118184742A (zh) | 缓解吡虫啉诱导免疫损伤的带鱼免疫肽fafu-c及其制备方法 | |
| CN108794588B (zh) | 一种生物活性多肽fdptlhq及其制备方法和应用 | |
| CN108794595B (zh) | 一种生物活性多肽iyqmvha及其制备方法和应用 | |
| FR2639232A1 (fr) | Medicaments contenant une interleukine-2 glycosylee | |
| JPH04300898A (ja) | 新規糖タンパク複合体およびその製造方法 | |
| CN118547028B (zh) | 一种对宠物腹泻具有治疗作用的多糖组合物 | |
| CN115894619B (zh) | 一种短肽、一种蛋白核小球藻多肽提取物及其制备方法和应用 | |
| CN1962691A (zh) | 胸腺四肽活性异构体及制备方法以及医药用途 | |
| RU2306950C2 (ru) | Комплексная аутологичная вакцина против вич-инфекции и спид |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |